# Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

> **NCT03127215** · PHASE2 · COMPLETED · sponsor: **National Center for Tumor Diseases, Heidelberg** · enrollment: 102 (actual)

## Conditions studied

- Cancers With DNA Repair-Deficiency

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Physician's choice
- **DRUG:** Trabectedin

## Key facts

- **NCT ID:** NCT03127215
- **Lead sponsor:** National Center for Tumor Diseases, Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-25
- **Primary completion:** 2023-12-19
- **Final completion:** 2023-12-19
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2024-05-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03127215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03127215, "Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03127215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*